Resource impact summary report
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.
Recommendation
Durvalumab can be used, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults. Durvalumab can only be used if the company provides it according to the commercial arrangement.
Eligible population for durvalumab
Table 1 shows the population who are eligible for durvalumab and the number of people who are expected to have durvalumab in each of the next 5 years, including forecast population growth.
| Eligible population and uptake | People eligible for durvalumab | Uptake for durvalumab (%) | People having durvalumab each year |
|---|---|---|---|
|
Current practice without durvalumab |
520 |
0 |
0 |
|
Year 1 |
525 |
45 |
236 |
|
Year 2 |
530 |
90 |
477 |
|
Year 3 |
534 |
90 |
481 |
|
Year 4 |
539 |
90 |
485 |
|
Year 5 |
544 |
90 |
489 |
The following assumptions have been used to calculate the eligible population:
-
Based on Cancer Registrations Statistics (England 2022), it is estimated that around 3,200 adults are diagnosed with small-cell lung cancer (SCLC) each year.
-
31.47% are assumed to have limited-stage SCLC as per a study by Khakwani et al. (2014).
-
The National Lung Cancer Audit's State of the Nation Report 2024 shows 55.5% of people with SCLC have a performance status of 0-1. It is assumed this group will receive chemoradiotherapy. This assumption can be adjusted in the template.
-
92% of people who receive chemoradiotherapy will not experience progression of their disease as per the company submission and are eligible for treatment with durvalumab.
-
Uptake for durvalumab is based on clinical expert opinion.
Treatment options for the eligible population
Durvalumab is used in addition to active monitoring when the cancer has not progressed. It is administered intravenously.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Financial resource impact (cash items)
The key drivers of financial resource impact are:
-
the drug costs and additional administrations, oncologist appointments required while on durvalumab rather than active monitoring
-
a decreased need for subsequent treatment costs along with any savings for associated administrations, appointments and scans.
The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount.
Users can input the confidential price of durvalumab and amend other variables in the resource impact template.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
For further analysis or to calculate the financial impact of cash items, see the resource impact template.
Capacity impact
Table 2 shows the impact on capacity activity in each of the next 5 years.
| Capacity impact | Number of administration appointments (not accounting for subsequent treatments) | Number of CT scans (chest and abdomen scans) | Number of follow-up attendances |
|---|---|---|---|
|
Current practice (without durvalumab) |
0 |
6,211 |
9,326 |
|
Year 1 |
3,047 |
7,678 |
10,714 |
|
Year 2 |
6,148 |
7,832 |
10,787 |
|
Year 3 |
6,202 |
8,139 |
11,120 |
|
Year 4 |
6,257 |
8,210 |
11,218 |
|
Year 5 |
6,312 |
8,282 |
11,317 |
For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.
Key information
| Time from publication to routine commissioning funding |
90 days |
|---|---|
| Programme budgeting category |
2D Cancers & Tumours – Lung |
| Commissioner |
NHS England |
| Provider |
NHS hospital trusts |
| Pathway position |
Post surgery and after platinum-based radiochemotherapy |
About this resource impact summary report
This resource impact summary report accompanies the NICE technology appraisal guidance on Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy and should be read with it.
ISBN: 978-1-4731-7233-3
This page was last updated: